MRT Inc.
Supplementary Materials for Q3 Fiscal Year Ending December 2026
For Q3 of the fiscal year ending December 2026, consolidated revenue was 3,063 million yen, up 3.3% year-over-year, and operating income improved substantially to 205 million yen. Reflecting the exclusion of physician-supervised product development and sales as discontinued operations, profit before tax was 201 million yen. Full-year forecast expects revenue of 3,950 million yen and operating income of 195 million yen.
Key Figures
- Revenue: 3,063 million yen
- Operating Income: 205 million yen
- Net Income Attributable to Owners of Parent: 114 million yen
AI要約
Performance Overview
For Q3 of the fiscal year ending December 2026, consolidated revenue was 3,063 million yen, representing a 3.3% increase year-over-year. Contribution from physician value-creation activities continued, and the impact of excluding physician-supervised product development and sales as discontinued operations is reflected. Operating income increased significantly to 205 million yen, and profit before tax remained solid at 201 million yen.
Full-Year Outlook and Investment Plan
Full-year revenue is forecast at 3,950 million yen and operating income at 195 million yen. The company will continue to invest proactively in building its membership base and in overseas operations, aiming for record revenue from permanent (career change) placement services. Since the outlook assumes exclusion of discontinued operations, attention should be paid to related caveats going forward.
MRT Inc.
Company overview · Stock price · Financial data · All IR
